Immunitybio Inc (IBRX) — Strategic Asset Allocation Index
Immunitybio Inc (IBRX) has a Strategic Asset Allocation Index of 40.7% as of June 2020. Strategic assets (PP&E of $69.02 Million plus long-term investments of $-) total $69.02 Million, measured against net assets of $169.65 Million. A higher index reflects capital-intensive or investment-heavy strategies where strategic assets dominate the equity base. See Immunitybio Inc balance sheet independence to measure how much of total assets are equity-financed.
SAAI
Strategic Assets
PP&E
Net Assets
Immunitybio Inc Strategic Asset Allocation Index (2016–2019)
This chart shows how Immunitybio Inc's Strategic Asset Allocation Index has evolved across 4 annual periods from 2016 to 2019. As of June 2020, the index stands at 40.7%, representing strategic assets of $69.02 Million against net assets of $169.65 Million USD. For live market cap and overall valuation, see Immunitybio Inc market cap and net worth.
Annual Strategic Asset Allocation Index for Immunitybio Inc (2016–2019)
The table below presents the year-by-year Strategic Asset Allocation Index for Immunitybio Inc from 2016 to 2019, covering 4 annual filings. Each row shows PP&E, long-term investments, strategic assets combined, net assets, the index percentage, and the change in percentage points compared to the prior year. See Immunitybio Inc book value and equity for net asset value and shareholders' equity analysis.
| Year | SAAI | Strategic Assets (USD) | PP&E | LT Investments | Net Assets | Change (pp) |
|---|---|---|---|---|---|---|
| 2019 | 23.0% | $27.78 Million | $27.78 Million | $- | $120.68 Million | ▲ +2.7 pp |
| 2018 | 20.3% | $29.63 Million | $29.63 Million | $- | $146.01 Million | ▼ -14.8 pp |
| 2017 | 35.1% | $76.73 Million | $76.73 Million | $- | $218.84 Million | ▲ +28.5 pp |
| 2016 | 6.6% | $19.38 Million | $19.38 Million | $- | $293.42 Million | — |